Quantcast

Latest Adalimumab Stories

2010-08-31 07:00:00

EXTON, Pa., Aug. 31 /PRNewswire/ -- BioTrends has released the third and final wave of LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first humanized IL-6 receptor inhibitor agent approved for moderate-to-severe rheumatoid arthritis (RA) patients with an inadequate response to one or more TNF-alpha inhibitors. This report is derived from on-line survey responses from 75 rheumatologists and qualitative interviews with a subset of the...

2010-08-31 04:29:00

DALLAS, August 31, 2010 /PRNewswire/ -- More than 10,00,000 new cases of skin nonmelanoma cancer has been reported for the current year only in U.S. This enhanced the market for anti skin cancer drugs and therapies within the dermatology market. Dermatology continues to remain one of the promising sectors within the pharmaceutical market due to recent drug developments in the respective area. Acne, dermatitis, psoriasis continue to generate major revenues for the market. Further,...

2010-08-09 07:00:00

WALTHAM, Mass., Aug. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of marketed and emerging interleukin and TNF-alpha inhibitors and a twofold increase in the penetration of biologics in the moderate-to-severe population will drive the psoriasis drug market to double from $3.4 billion in 2009 to $6.8 billion in 2019 in the United States, France, Germany, Italy, Spain,...

2010-08-02 07:00:00

WALTHAM, Mass., Aug. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 63 percent of surveyed U.S. gastroenterologists prescribe Abbott's Humira off-label for the treatment of ulcerative colitis. According to the new report entitled Treatment Algorithms in Ulcerative Colitis, surveyed gastroenterologists most often prescribe Humira for ulcerative colitis for patients with loss of response,...

2010-07-30 13:30:29

Reported cancers are uncommon in children, associated with immunosuppression The Food and Drug Administration (FDA) received reports of malignancies in children using tumor necrosis factor a (TNF) blockers, raising concerns of an associated risk and prompting an investigation. Researchers from the FDA set out to identify all reports of malignancy in children using infliximab, etanercept, and adalimumab and their report is published in the August issue of Arthritis & Rheumatism, a journal...

2010-07-28 09:00:00

WALTHAM, Mass., July 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the rheumatoid arthritis (RA) drug market, the uptake of alternative biologics such as Roche/Chugai's Actemra/RoActemra will erode the market share of TNF-alpha inhibitors over the next decade. Actemra/RoActemra will emerge as the likely preferred biologic agent for TNF-refractory patients and will garner blockbuster...

2010-06-02 04:30:00

LOS ANGELES, June 2 /PRNewswire/ -- Two new studies suggest that excess levels of a protein associated with inflammation, TNF, may produce cognitive decline. TNF regulates both inflammation and brain function. TNF is elevated in the blood in many autoimmune diseases, and in the fluid surrounding the brain in Alzheimer's disease. The new studies, from medical centers in Taiwan and the Netherlands, examined cognitive function in patients with either of two autoimmune diseases, rheumatoid...

2010-05-26 08:26:00

EXTON, Pa., May 26 /PRNewswire/ -- BioTrends released the final wave of LaunchTrends(®): Stelara, a three wave syndicated report that has been tracking the uptake of the product since launch. In the final wave of research, which measures success at the six months post launch mark, BioTrends surveyed 76 clinical dermatologists and conducted qualitative interviews with a subset of 20 of the respondents. Compared to the prior wave, which measured uptake at three months...

2010-05-06 07:00:00

EXTON, Pa., May 6 /PRNewswire/ -- BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Rheumatoid Arthritis. This report covers the use of biologics for the treatment of rheumatoid arthritis (RA). The report, part of a quarterly series, focuses on current and future use of biologic agents, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived...

2010-05-02 23:01:00

LONDON, May 3, 2010 /PRNewswire/ -- The rheumatoid arthritis treatment Humira will replace Lipitor as the world's biggest-selling drug in 2016, but a familiar name, Pfizer, will still be the biggest seller of medicines after the patent cliff according to the World Preview 2016 report published today by EvaluatePharma, the premier provider of pharma and biotech analysis. The cancer treatment Avastin had been widely expected to emerge as the biggest blockbuster drug following patent...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.